NGNE - Neurogene Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$69.67
DETAILS
HIGH:
$70.00
LOW:
$69.00
MEDIAN:
$70.00
CONSENSUS:
$69.67
UPSIDE:
82.19%
About Neurogene Inc. (https://www.neurogene.com)
Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease). The company's operations are based in New York, New York.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Rachel L. McMinn | Founder, Executive Chair & Chief Executive Officer | 1973 | $997,237 USD |
| Christine Mikail Cvijic | President, CFO & Director | 1978 | $874,062 USD |
| Julie Jordan | Chief Medical Officer | 1972 | $696,339 USD |
| Stuart Cobb | Chief Scientific Officer | 1971 | $478,807 USD |
| Andrew E. Mulberg FAAP | Senior Vice President of Regulatory Affairs, Quality Assurance & Quality Control | – | – |
| Arvind Sreedharan | Senior Vice President of Business Operations | – | – |
| Christina Shafer | Chief Commercial Officer | 1976 | – |
| Donna Cochener-Metcalfe | Senior Vice President, General Counsel & Corporate Secretary | 1975 | – |
| Ricardo Jimenez | Senior Vice President of Technical Operations | – | – |